- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01331252
Pneumonia in Tetanus Study (BP)
Can the Incidence of Nosocomial Pneumonia in Severe Tetanus be Reduced by Nursing Patients Semi-recumbent? A Randomised Comparison of Supine or Semi-recumbent Body Position
Study Overview
Detailed Description
Background: Hospital-acquired pneumonia remains a common and important cause of morbidity and mortality in patients with severe tetanus who require a tracheostomy whether or not they are mechanically ventilated. We propose to investigate if the incidence of hospital-acquired pneumonia can be reduced by nursing tetanus patients semi-recumbent at 30o rather than supine as is the current practice.
The aim of this study will be to assess the frequency of clinically suspected and microbiologically confirmed hospital acquired pneumonia in patients nursed in a semi-recumbent or supine body position. A secondary end-point will be the mortality in each group. Patients at risk of developing hospital acquired pneumonia (in hospital without developing pneumonia for more than two days) will be evaluated
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consecutive patients will be entered into the study as they are admitted to the intensive care ward with a clinical diagnosis of tetanus.
- Informed consent will be obtained from the patient or next-of-kin before randomisation.
- An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (300) or supine (00) body position. The randomisation will be created by a computer generated list.
- All health care personnel will be instructed not to change the position, unless for medical requirements.
- The correctness of the position will be checked twice daily.
- Surveillance for clinical detection of pneumonia or other infection will be done daily. If infection is suspected relevant microbiological samples will be taken.
- The study period will end 72 hours after the patient has left the intensive care ward, or if there is a permanent change in body position for more than 1 hour or death.
Exclusion Criteria:
- Recent abdominal surgery (<7 days)
- Shock refractory to vasoactive drugs or volume therapy
- Recent intensive care (<30 days)
- Neonates
- Pneumonia at the time of admission to intensive care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: supine body position
Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study.
An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
|
Patient rests in a supine position
|
Experimental: semi-recumbent
Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study.
An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
|
Patient rests in a semi-recumbent body position
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assess the frequency of clinically suspected and microbiologically confirmed hospital acquired pneumonia
Time Frame: 72 hours
|
assess the frequency of clinically suspected and microbiologically confirmed hospital acquired pneumonia in patients nursed in a semi-recumbent or supine body position
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mortality between supine or semi-recumbent body position
Time Frame: 72 hours
|
mortality in each group.
Patients at risk of developing hospital acquired pneumonia (in hospital without developing pneumonia for more than two days) will be evaluated
|
72 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christopher Parry, MD, Oxford University Clinical Research Unit - Viet Nam
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nervous System Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Neurologic Manifestations
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Neuromuscular Manifestations
- Clostridium Infections
- Hypocalcemia
- Calcium Metabolism Disorders
- Pneumonia
- Tetanus
- Tetany
Other Study ID Numbers
- BP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tetanus
-
National Institute of Allergy and Infectious Diseases...Completed
-
Jiangsu Province Centers for Disease Control and...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedBacterial Infections | Group B StreptococcusUnited States
-
Changchun BCHT Biotechnology Co.The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaboratorsNot yet recruiting
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
EpicentreCompletedTetanus | Tetanus VaccineChad
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Tetanus | Diphtheria | Diphtheria Immunisation | Tetanus Immunisation | Clostridium Difficile ImmunisationMali
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDiphtheria, Tetanus and PertussisSpain
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownColorectal CancerUnited States, Canada
Clinical Trials on supine
-
University of NancyCentral Hospital, Nancy, FranceCompleted
-
Hospices Civils de LyonCompleted
-
Akdeniz UniversityCompletedPreterm Birth | Preterm Infant | Ventilator Lung; NewbornTurkey
-
University Eye Hospital, FreiburgCompletedFuchs' Endothelial DystrophyGermany
-
Hospices Civils de LyonCompleted
-
University of ExeterRoyal Devon and Exeter NHS Foundation TrustCompletedSVT | Vagal BradycardiaUnited Kingdom
-
Osaka UniversityHospital RebagliatiUnknown
-
Dartmouth-Hitchcock Medical CenterCompletedBreast CancerUnited States
-
Milton S. Hershey Medical CenterDysautonomia InternationalCompletedPostural Tachycardia Syndrome | Ehlers-Danlos SyndromeUnited States
-
Changhai HospitalNo.85 Hospital, Changning, Shanghai, ChinaCompleted